Abstract
The clinical, radiographic, and histopathologic features of ILD in myositis are similar to idiopathic ILD. Patients with a known diagnosis of inflammatory myopathy require a prompt clinical evaluation and the assessment of myositis-associated autoantibodies. Patients possessing autoantibodies associated with ILD or those with any pulmonary symptoms should have pulmonary functions test and high resolution CT (HRCT) scanning of their lungs. Despite the lack of placebocontrolled trials, systemic glucocorticoids are considered the mainstay of initial treatment of myositisassociated ILD. Glucocorticoid-sparing agents are often started concomitantly with glucocorticoids, particularly in patients with severe disease. The first-line conventional immunosuppressive drugs include either mycophenolate mofetil or azathioprine. If these agents fail or if the features are more severe or rapidly progressive, then more aggressive immunosuppressive or immunomodulatory therapy including cyclophosphamide, tacrolimus or cyclosporine, or rituximab should be considered. Further investigations are required to assess the role of novel therapies in the treatment of myositis-associated ILD.
Keywords: Dermatomyositis, idiopathic inflammatory myopathy, interstitial lung disease, myositis, polymyositis, pulmonary fibrosis, treatment.
Current Respiratory Medicine Reviews
Title:Interstitial Lung Disease in Myositis
Volume: 11 Issue: 2
Author(s): Siamak Moghadam-Kia, Chester V. Oddis and Rohit Aggarwal
Affiliation:
Keywords: Dermatomyositis, idiopathic inflammatory myopathy, interstitial lung disease, myositis, polymyositis, pulmonary fibrosis, treatment.
Abstract: The clinical, radiographic, and histopathologic features of ILD in myositis are similar to idiopathic ILD. Patients with a known diagnosis of inflammatory myopathy require a prompt clinical evaluation and the assessment of myositis-associated autoantibodies. Patients possessing autoantibodies associated with ILD or those with any pulmonary symptoms should have pulmonary functions test and high resolution CT (HRCT) scanning of their lungs. Despite the lack of placebocontrolled trials, systemic glucocorticoids are considered the mainstay of initial treatment of myositisassociated ILD. Glucocorticoid-sparing agents are often started concomitantly with glucocorticoids, particularly in patients with severe disease. The first-line conventional immunosuppressive drugs include either mycophenolate mofetil or azathioprine. If these agents fail or if the features are more severe or rapidly progressive, then more aggressive immunosuppressive or immunomodulatory therapy including cyclophosphamide, tacrolimus or cyclosporine, or rituximab should be considered. Further investigations are required to assess the role of novel therapies in the treatment of myositis-associated ILD.
Export Options
About this article
Cite this article as:
Moghadam-Kia Siamak, Oddis V. Chester and Aggarwal Rohit, Interstitial Lung Disease in Myositis, Current Respiratory Medicine Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573398X11666150619184220
DOI https://dx.doi.org/10.2174/1573398X11666150619184220 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Contractile Properties of Airway Smooth Muscle: How their Defects can be Linked to Asthmatic Airway Hyperresponsiveness?
Current Respiratory Medicine Reviews Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Snake Venom Prothrombin Activators Similar to Blood Coagulation Factor Xa
Current Drug Targets - Cardiovascular & Hematological Disorders Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews Rheumatologic Manifestations of Hematologic Neoplasms
Current Rheumatology Reviews The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Conformations and Biological Activities of Amyloid Beta Peptide 25-35
Current Protein & Peptide Science A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Applications of Animal Models of Infectious Arthritis in Drug Discovery:A focus on Alphaviral Disease
Current Drug Targets Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study
Current Drug Discovery Technologies Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma
Current Drug Safety Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery The Haywain: Anti-synthetase Antibodies in Patients with Inflammatory Diseases: Targeting Monocytes or Neutrophils?
Current Medicinal Chemistry Methods of Masseter and Temporal Muscle Thickness and Elasticity Measurements by Ultrasound Imaging: A Literature Review
Current Medical Imaging Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews